Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 7/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | TDP2 | O95551 | 2/20 | 0.48 |
| ▸ | PTPRC | P08575 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469256 | 1.00 | MAPT (0.56) | MAPTLMNAALDH1A1MEN1NPC1 | |
| SCHEMBL2608412 | 0.88 | KEAP1 (0.59) | MAPTLMNAALDH1A1MEN1NPC1 | |
| SCHEMBL30363830 | 0.87 | TSHR (0.48) | MAPTLMNAALDH1A1MEN1NPC1 | |
| SCHEMBL30469296 | 0.87 | LMNA (0.52) | MAPTLMNAALDH1A1MEN1NPC1 | |
| SCHEMBL20557478 | 0.87 | LMNA (0.52) | MAPTLMNAALDH1A1MEN1NPC1 | |
| SCHEMBL15293412 | 0.86 | RXRA (0.46) | MAPTLMNAALDH1A1MEN1NPC1 | |
| SCHEMBL7838339 | 0.82 | LMNA (0.64) | MAPTLMNAALDH1A1MEN1NPC1 | |
| SCHEMBL4516641 | 0.82 | TSHR (0.64) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL2660487 | 0.82 | NPBWR1 (0.54) | MAPTLMNAALDH1A1MEN1NPC1 | |
| SCHEMBL6738366 | 0.82 | TSHR (0.76) | MAPTLMNAALDH1A1MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE | 2025-07-15 | — | — | US | disclosed |
| CN-116283668-A | Diaryl ureas as CB1 allosteric modulators | 研究三角协会 | 2023-06-23 | — | — | CN | disclosed |
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2021-10-28 | — | — | US | disclosed |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2021-08-10 | — | — | US | disclosed |
| EP-3621951-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | Research Triangle Institute (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-27 | — | — | US | disclosed |
| CN-110621656-A | Diaryl ureas as CB1 allosteric modulators | 研究三角协会 | 2019-12-27 | — | — | CN | disclosed |
| WO-2018209030-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | RTI INTERNATIONAL (US) | 2018-11-15 | — | — | WO | disclosed |
| US-20120088757-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-12 | — | — | US | disclosed |
| US-7947684-B2 | anticoagulants; immunomoderators; antiinflammatory agents | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | MAPT 2523/4885LMNA 4699/4885ALDH1A1 2918/4885 |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | MAPT 2523/4885LMNA 4699/4885ALDH1A1 2918/4885 |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR18 | MAPT 2523/4885LMNA 4699/4885ALDH1A1 2918/4885 |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | ATP5F1A, ATP5MF, MT-ATP6 | MAPT 2229/4885LMNA 2704/4885ALDH1A1 1703/4885 |
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR18 | MAPT 2523/4885LMNA 4699/4885ALDH1A1 2918/4885 |
| US-20120088757-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | BAD, GABRA5, GABRB1 | MAPT 2884/4885LMNA 3184/4885ALDH1A1 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.